HOME > BUSINESS > Dr Reddy’s Labs launches osteoporosis drug in the US

Dr Reddy’s Labs launches osteoporosis drug in the US

Dr Reddy’s Laboratories Ltd said it launched raloxifene hydrochloride tablets –used to treat osteoporosis — in the US market.

Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use.

Raloxifene is used by women to prevent and treat bone loss (osteoporosis) after menopause. It slows down bone loss and helps to keep bones strong, making them less likely to break.

Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive breast cancer) after menopause.

The Evista brand and generic had US sales of approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health.

Dr. Reddy’s Raloxifene tablets are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista is a registered trademark of Eli Lilly and Company.

The Food and Drug Administration (FDA or USFDA) is a federal agency of the United States Department of Health and Human Services, one of the United States federal executive departments. The FDA is responsible for protecting and promoting public health through the control and supervision of food safety, tobacco products, dietary supplements, prescription and pharmaceutical drugs, vaccines, biopharmaceuticals etc.

Dr. Reddy’s Laboratories Ltd. is an India pharmaceutical company and offers products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Follow ULTRA.news
Zydus Cadila gets approval for two drugs in the US Zydus Cadila said it received the final regulatory approval to market anti-sleep drug Modafinil in the US, and tentative approval for bladder control drug Solifenacin Succinate.Unlike a final approval, tentative approvals don't allow the grantee to sell the drugs in the US m...
TCS launches AI-based IT incident prevention solution in Japan Tata Consultancy Services launched its artificial intelligence-based IT repair and prevention solution, ignio, in Japan."When System outages occur today, businesses dedicate vast resources to rectify the problem. Oftentimes, multiple teams are called together to identify the...
Lupin gets nod to launch Metronidazole antibiotic in the US Lupin said it received final approval to market a generic version of G.D. Searle LLC Flagyl antibiotic tablets in the US.Flagyl tablets had US sales of USD 44.1 millionLupin’s Metronidazole Tablets USP, 250 mg and 500 mg are the AB rated generic equivalent of the drug. ...
Lupin gets UDFDA nod for generic version of Pfizer’s acne drug Pharma company Lupin said it received final approval from the US Food and Drug Administration for launching a generic version of Pfizer Inc.'s acne drug Vibra-Tabs.Doxycycline Hyclate Tablet 100 mg had US sales of USD 149.9 million per year, the company said.Doxycycline ...
Panacea Biotec to supply heart drug to Apotex for US market Pharma company Panacea Biotec said it has signed an agreement to supply a generic version of Eli Lilly's Effient heart drug to Apotex, the largest Canadian-owned pharmaceutical company.The drug will be sold by Apotex in the US market."Under the terms of the agreement, Ap...
Zydus Cadila to launch immuno-suppressant in the US Pharma giant Zydus Cadila said it received final approval from the USFDA to market immunonsuppressant Mycophenolate Mofetil injection.The drug is indicated for use in combination with other drugs i.e., cyclosporine and corticosteroids for the prophylaxis of organ rejection ...
Dr Reddy’s hit by class action suit on “misleading statements” on FDA action Pharma giant Dr Reddy's Labs today said that a class action lawsuit has been filed against it on behalf of shareholders, alleging that the company misled investors causing them to lose money on their investments."The lawsuit alleges that the company made materially false and...
Jubilant Life Sciences gets US-FDA approval for pain drug Pharma company Jubilant Life Sciences Ltd said it received final approval to sell pain drug Indomethacin in the US.The drug, which is also sold as Indocin by Iroko in the US, is a nonsteroidal anti-inflammatory drug used for the treatment of moderate to severe inflammation a...
Glenmark Pharma gets USFDA approval for generic version of Mylan’s anti-inflammation ointment Glenmark Pharmaceuticals said it has got the US FDA approval to sell the generic version of corticosteroid ointment Kenalog from Mylan Pharmaceuticals.The primary ingredient is triamcinolone, a corticosteroid that reduces the actions of chemicals in the body that cause inflam...
Aurobindo Pharma HIV drug gets USFDA approval under PEPFAR Aurobindo Pharma said it received tentative approval for its for anti-HIV drug Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate under the U.S. President's Emergency Plan for AIDS Relief or PEPFAR.The approved product is used for the treatment of HIV-1 infection alon...
India draws closer to US under Modi, to restart ‘COPE INDIA’ The Narendra Modi-led National Democratic Alliance government of India is ramping up defense cooperation with the United States, and will restart COPE INDIA, a mock combat exercise between the US and Indian Air Force.COPE INDIA was first conducted in 2004, and subsequently in...
Lupin gets FDA nod for generic cholesterol drug Pharmaceuticals company Lupin said it received a 505 (b)(2) NDA approval for its Nikita"M (Pitavastatin) Tablets 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA).A 505(b)(2) approval refers to one given by relying on studies already performed on a...
Zydus Cadila gets USFDA nod for chemo, BP drugs Zydus Cadila said it has received approval from the US Food and Drug Administration to market chemotherapy drug Temozolomide and blood pressure drug Nadolol.Temozolomide will be made available in six doses from 5 mg to 250 mg.It is used in the management of brain tumors....
Strides Shasun to launch allergy drug in the US Pharma company Strides Shasun said it had received approval allergy drug Cetirizine Hydrochloride in the US."The US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately USD 60 mln, with only one other generic player," the company said."The product is re...
Pakistan Army protests cross-border attacks by India Pakistan's Director General of Military Operations protested Indian attacks on the Line of Control in Kashmir in a meeting with his Indian counterpart.According to a statement released by the Indian side, Pakistan complained that Indian Army had killed four Pakistani soldiers...
Glenmark gets US FDA approval for generic version of Daiichi Sankyo’s hypertension drug Glenmark Pharmaceuticals said it got approval from US authorities to launch a generic version of Daiichi Sankyo's hypertension drug Azor in various dosages.The drug had annual sales of approximately $211.6 million as of May.The approval was obtained from United States Foo...
Jubilant Life Sciences gets USFDA nod for anti-depressant Jubilant Life Sciences said it received final approval from US authorities to launch a generic version of Valeant's anti-depressant Wellbutrin.The approval from FDA is for introducing Bupropion Hydrochloride tablets in 150 mg and 300 mg doses.The drug is used for the tre...
Lupin launches eye drug in the US Pharma company Lupin said it launched Moxifloxacin Hydrochloride eye solution in the US.Lupin's Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.'s Vigamox Ophthalmic solution.It is indicated for...
Zydus Cadila starts Phase II trial on anemia drug for kidney patients Zydus said it started phase II trial on its anemia drug candidate ZYAN1.The drug, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being tested as a treatment for anemia associated with chronic kidney disease (CKD).The move follows successful Phase 1 trials. A ...
Zydus Cadilla gets preliminary USFDA nod for diabetes treatment Zydus Cadila has received the tentative approval from the USFDA to market Sitagliptin and Metformin Hydrochloride Tablets used for controlling blood sugar levels."This is a fixed dose combination of two anti-diabetic drugs indicated for Type II diabetes mellitus and will be p...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Sun Pharma selects Samsung to manufacture psoriasis drug Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.Plaque psoriasis is an autoimmune condition which results in patches of ...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...